LY-2459989
 | |
| Systematic (IUPAC) name | |
|---|---|
|
3-Fluoro-4-[4-[[(2S)-2-pyridin-3-ylpyrrolidin-1-yl]methyl]phenoxy]benzamide | |
| Clinical data | |
| Routes of administration | Oral, intravenous |
| Pharmacokinetic data | |
| Biological half-life | 15 minutes (in rhesus monkeys)[1] |
| Identifiers | |
| ATC code | None |
| Chemical data | |
| Formula | C23H22FN3O2 |
| Molar mass | 391.444 g/mol |
| |
| |
LY-2459989 is a silent antagonist of the κ-opioid receptor (KOR) that has been developed by Eli Lilly as a radiotracer (labeled with carbon-11) of the aforementioned receptor.[1] It possesses high affinity for the KOR (Ki = 0.18 nM) and is highly selective for it over the μ-opioid receptor (Ki = 7.68 nM) and the δ-opioid receptor (Ki = 91.3 nM) (over 43-fold selectivity for the KOR over the other opioid receptors).[1] LY-2459989 is a fluorine-containing analogue and follow-up compound of LY-2795050, the first-ever KOR-selective antagonist radiotracer.[1] Relative to LY-2795050, LY-2459989 displays 4-fold higher affinity for the KOR and similar selectivity and also possesses greatly improved central nervous system permeation (brain levels were found to be 6-fold higher than those of LY-2795050).[1] The drug appears to possess a short duration of action, with only 25% remaining in serum at 30 minutes post-injection in rhesus monkeys, making it an ideal agent for application in biomedical imaging, for instance in positron emission tomography (PET).[1]
Earlier analogues of LY-2459989 besides LY-2795050 with similar actions and potential uses have also been described.[2]
See also
- CERC-501 (LY-2456302)
- Buprenorphine
- Carfentanil
- Diprenorphine
- GR-89696
- Naltrexone
- Naltriben
References
- 1 2 3 4 5 6 Zheng, M.-Q.; Kim, S. J.; Holden, D.; Lin, S.-f.; Need, A.; Rash, K.; Barth, V.; Mitch, C.; Navarro, A.; Kapinos, M.; Maloney, K.; Ropchan, J.; Carson, R. E.; Huang, Y. (2014). "An Improved Antagonist Radiotracer for the -Opioid Receptor: Synthesis and Characterization of 11C-LY2459989". Journal of Nuclear Medicine 55 (7): 1185–1191. doi:10.2967/jnumed.114.138701. ISSN 0161-5505.
- ↑ Mitch CH, Quimby SJ, Diaz N, Pedregal C, de la Torre MG, Jimenez A, Shi Q, Canada EJ, Kahl SD, Statnick MA, McKinzie DL, Benesh DR, Rash KS, Barth VN (2011). "Discovery of aminobenzyloxyarylamides as κ opioid receptor selective antagonists: application to preclinical development of a κ opioid receptor antagonist receptor occupancy tracer". J. Med. Chem. 54 (23): 8000–12. doi:10.1021/jm200789r. PMID 21958337.